Skip to main content

Table 4 Demographic and clinical factors associated with having a low MCS or PCS component summary score

From: The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa

  Mental component summary score Physical component summary score
N, % (n = 74) Crude RR (95% CI) Adjusted RR (95% CI) N, % (n = 75) Crude RR (95% CI) Adjusted RR (95% CI)
Adverse event
 Adverse event not reported 31/91 (34.1%) 1.00 1.00 35/91 (38.5%) 1.00 1.00
 Adverse event reported 43/58 (74.1%) 2.18 (1.57–3.01) 2.24 (1.53–3.27) 40/58 (69.0%) 1.79 (1.31–2.45) 1.52 (1.07–2.18)
Sex
 Male 39/82 (47.6%) 1.00 1.00 41/82 (46.1%) 1.00 1.00
 Female 35/67 (52.2%) 1.10 (0.79–1.52) 1.23 (0.81–1.84) 34/67 (54.8%) 1.01 (0.74–1.40) 1.10 (0.71–1.68)
Age at treatment initiation (years)
 18–35 39/74 (52.7%) 1.00 1.00 37/74 (50.0%) 1.00 1.00
  > 35+ 35/75 (46.7%) 0.89 (0.64–1.23) 0.91 (0.62–1.34) 38/75 (50.7%) 1.01 (0.74–1.40) 0.86 (0.56–1.31)
Education
 Secondary school and higher 67/135 (49.6%) 1.00   71/135 (52.6%) 1.00  
 Primary school or less 7/14 (50.0%) 1.01 (0.58–1.75)   4/14 (28.6%) 0.54 (0.23–1.27)  
Employment Status
 Unemployed 45/85 (52.9%) 1.00   45/85 (52.9%) 1.00  
 Employed 28/63 (44.4%) 0.84 (0.60–1.18)   29/63 (44.4%) 0.87 (0.62–1.22)  
Resistance Pattern
 RIF resistant by Xpert MTB/RIF 21/38 (55.2%) 1.00 1.00 21/38 (55.2%) 1.00 1.00
 RIF mono-resistant (INH sensitive) 30/67 (44.8%) 0.81 (0.55–1.20) 0.89 (0.55–1.45) 29/67 (43.3%) 0.78 (0.53–1.17) 0.88 (0.55–1.41)
 MDR-TB (RIF and INH resistant) 14/32 (43.8%) 0.79 (0.49–1.29) 1.09 (0.67–1.78) 16/32 (50.0%) 0.90 (0.58–1.42) 1.15 (0.66–1.99)
 Missing 9/12 (75.0%) 1.36 (0.88–2.09) 0.98 (0.59–1.64) 9/12 (75.0%) 1.36 (0.88–2.09) 1.26 (0.81–1.95)
HIV Status
 HIV negative 11/27 (40.7%) 1.00   13/27 (48.1%) 1.00  
 HIV positive and on ART 45/94 (47.9%) 1.18 (0.71–1.94)   44/94 (46.8%) 0.97 (0.62–1.52)  
 HIV positive not on ART 14/22 (63.6%) 1.56 (0.90–2.72)   15/22 (68.2%) 1.42 (0.87–2.30)  
 Missing 4/6 (66.7%) 1.64 (0.79–3.39)   3/6 (50.0%) 1.04 (0.42–2.54)  
Baseline CD4#
  ≤ 250 (n = 78) 39/78 (50.0%) 1.00   41/78 (52.6%) 1.00 1.00
  > 250 (n = 31) 16/31 (51.6%) 1.03 (0.69–1.55)   12/31 (38.7%) 0.74 (0.45–1.21) 0.82 (0.45–1.50)
 CD4 count unknown (n = 7) 4/7 (57.1%) 1.14 (0.58–2.56)   6/7 (85.7%) 1.63 (1.13–2.36) 1.04 (0.55–1.94)
Indications for DR-TB regimen
 Standard regimen (long- or short-course) 55/107 (51.4%) 1.14 (0.78–1.66) 1.49 (1.00–2.24) 54/107 (50.5%) 1.01 (0.71–1.44)  
 Individualized regimen (injection free) 19/42 (45.2%) 1.0 1.0 21/42 (50.0%) 1.0  
Duration of DR-TB treatment (months)
  ≤ 6 months 49/66 (74.2%) 2.46 (1.72–3.53) 2.27 (1.53–3.35) 44/66 (66.7%) 1.78 (1.29–2.48) 1.70 (1.11–2.61)
  > 6 months 25/83 (30.1%) 1.0 1.0 31/83 (37.3%) 1.0 1.0
Duration of ART (months)&
  ≤ 6 months (n = 14) 10/14 (71.4%) 1.91 (1.21–3.02) 1.46 (0.96–2.23) 7/14 (50.0%) 1.24 (0.68–2.27) 0.98 (0.51–1.89)
  > 6 months (n = 67) 25/67 (31.3%) 1.0 1.0 27/67 (40.3%) 1.0 1.0
  ART start date unknown (n = 13) 10/13 (76.9%) 2.06 (1.34–3.18) 1.58 (0.96–2.59) 10/13 (76.9%) 1.91 (1.26–2.90) 1.58 (0.96–2.60)
Anaemia
 None or mild (Hb ≥11.0 g/dL) 29/64 (45.3%) 1.00   31/64 (48.8%) 1.00  
 Moderate (8–10.9 g/dL) or severe (< 8 g/dL) 14/26 (53.8%) 1.19 (0.76–1.86)   14/26 (53.8%) 1.11 (0.72–1.72)  
 Missing 31/59 (52.5%) 1.16 (0.81–1.67)   30/59 (50.8%) 1.05 (0.73–1.50)  
Weight at diagnosis (kg)
  < 50 kg 52/103 (50.5%) 1.00   51/103 (49.5%) 1.00  
  ≥ 50 kg 17/37 (45.9%) 0.91 (0.61–1.36)   18/37 (48.6%) 0.98 (0.67–1.44)  
 Missing 5/9 (55.6%) 1.10 (0.59–2.04)   6/9 (66.7%) 1.35 (0.81–2.23)  
Referring Facility
 Outpatient 47/100 (47.0%) 1.00   48/100 (48.0%) 1.00  
 Inpatient 27/49 (55.1%) 1.17 (0.84–1.63)   27/49 (55.1%) 1.15 (0.83–1.59)  
Patient Category
 New 47/90 (52.2%) 1.00   47/90 (52.2%) 1.00  
 Previously treated 13/36 (36.1%) 0.69 (0.43–1.12)   13/36 (36.1%) 0.69 (0.43–1.12)  
 Missing 14/23 (60.9%) 1.17 (0.79–1.71)   15/23 (65.2%) 1.25 (0.87–1.79)  
TB Type
 PTB and EPTB or EPTB only 11/24 (45.8%) 1.00   12/24 (45.8%) 1.00  
 PTB and not reported 63/125 (50.4%) 1.10 (0.69–1.76)   63/125 (50.4%) 1.01 (0.65–1.56)  
Smear Microscopy
 Negative 49/99 (49.5%) 1.00   48/99 (48.5%) 1.00  
 Positive 10/26 (38.5%) 0.78 (0.46–1.32)   12/26 (46.2%) 0.95 (0.60–1.51)  
 Missing 15/24 (62.5%) 1.26 (0.87–1.83)   15/24 (62.5%) 1.29 (0.89–1.87)  
  1. PTB pulmonary tuberculosis, EPTB extra pulmonary tuberculosis, DR-TB drug-resistant TB, MDR-TB multi-drug resistant TB, RR-TB rifampicin-resistant tuberculosis, RIF rifampicin, INH isoniazid, Hb hemoglobin
  2. # Among patients who are HIV positive (n = 116)
  3. & Among patients who are HIV positive and on ART (n = 94)
  4. a Standard long-course = 6 months of injectable kanamycin and 18–24 months of oral moxifloxacin, ethionamide, terizidone, and pyrazinamide
  5. b Individualized long-course = bedaquiline was introduced as a substitute for kanamycin in the standard long-course regimen (either at start of DR-TB or switched during treatment due to an incident adverse event)
  6. c Standard short-course = 4 to 6-month intensive phase of kanamycin, moxifloxacin, ethionamide, clofazimine, pyrazinamide and high-dose isoniazid followed by 5 months of moxifloxacin, clofazimine, pyrazinamide and ethambutol
  7. d Individualized short-course = bedaquiline was introduced as a substitute for kanamycin in the standard short-course regimen (either at start of DR-TB or switched during treatment due to an incident adverse event)